[Experimental basis for the use of new dosage forms of doxorubicin for correction of its hepatotoxic, prooxidant and immunosuppressory effects].

Prokopenko, L G; Lazarev, A I; Siplivyi, G V; Kukureka, A V; Siplivaia, L E; Karpenko, E N

[Experimental basis for the use of new dosage forms of doxorubicin for correction of its hepatotoxic, prooxidant and immunosuppressory effects]. / Eksperimental'noe obosnovanie ispol'zovaniia novykh lekarstvennykh form doksorubitsina dlia korrektsii ego gepatotoksicheskogo, prooksidatnogo i immunosupressornogo deistviia.

Prokopenko, L G; Lazarev, A I; Siplivyi, G V; Kukureka, A V; Siplivaia, L E; Karpenko, E N.

Antibiot Khimioter ; 49(4): 16-20, 2004.

Article in Ru | MEDLINE | ID: mdl-15460018

Subject(s)

Doxorubicin/administration & dosage; Drug Carriers; Methylcellulose; Animals; Doxorubicin/therapeutic use; Drug Evaluation, Preclinical; Drug Stability; Erythrocyte Membrane; Hepatocytes/metabolism; Immunosuppression Therapy; Injections, Intramuscular; Lipid Peroxidation; Pharmaceutic Aids; Rats; Rats, Wistar; Staphylococcal Infections/drug therapy; Staphylococcus aureus; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Drug Carriers / Doxorubicin / Methylcellulose Type of study: Qualitative_research Language: Ru Journal: Antibiot Khimioter Year: 2004 Type: Article

Search on Google

Add to My VHL

XML

PubMed Links